Latest Tax Incentives News

Page 1 of 64
Actinogen Medical’s pivotal XanaMIA trial produced a mixed result: Xanamem showed a small, non-significant benefit across the full 247-patient population, but a prespecified older-patient analysis found a statistically significant difference in disease stabilisation. The company will continue its open-label extension, suspend future Phase 3 spending and seek development partners.
Victor Sage
Victor Sage
19 Nov 2026
Wide Open Agriculture has secured a $1 million placement to fund manufacturing trials, commercial development and working capital as it targets a return to lupin ingredient production in Q2 2027. The raise strengthens its cash position, but production still depends on selecting a partner and completing technical validation.
Victor Sage
Victor Sage
13 Nov 2026
Australian Bond Exchange says FY2026 marked a sharper recovery, with revenue up 47% and two consecutive quarters of positive operating cash flow. But the ASX-listed fixed-income group remains loss-making, carries $2 million of convertible-note maturities in 2027 and faces a going-concern uncertainty.
Claire Turing
Claire Turing
13 Nov 2026
AdAlta has received a larger-than-expected A$1.396 million R&D Tax Incentive refund tied to overseas work on its EW-001 CAR-T therapy. The non-dilutive cash arrives before Australian manufacturing and expected FDA pre-IND meeting minutes in December.
Ada Torres
Ada Torres
12 Nov 2026
Starpharma is targeting a December start for first-in-human testing of its lead DEP HER2-Lu radiopharmaceutical, subject to ethics approval, as it shifts decisively toward targeted oncology. The company also outlined stronger funding, majority ownership of Petalion’s FAP program and a proposed Chair transition at its 2026 AGM.
Ada Torres
Ada Torres
6 Nov 2026
Neurizon Therapeutics has secured A$4.3 million through a discounted placement and is seeking another A$2.0 million from eligible shareholders, while redeeming its remaining Obsidian convertible notes. The move removes current note-conversion dilution, but shifts funding risk towards equity holders ahead of a pivotal NUZ-001 trial readout.
Ada Torres
Ada Torres
2 Nov 2026
Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.
Ada Torres
Ada Torres
2 Nov 2026
Activeport’s Q1 FY27 revenue rose 18% to A$1.72 million as software sales more than doubled, while a completed restructure promises A$2 million in annualised savings. The sharper growth story arrives with a pressing funding question: quarter-end cash covered only 0.7 quarters of reported operating outflows.
Sophie Babbage
Sophie Babbage
30 Oct 2026
CONNEQT Health ended the September quarter with just A$501,000 in cash after a A$3.06 million operating outflow, equivalent to 0.16 quarters of funding at the reported burn rate. The company is pursuing R&D-backed debt, inventory finance and an equity raising as Pulse sales recover from an inventory disruption.
Victor Sage
Victor Sage
30 Oct 2026
Proteomics International has begun the national rollout of its Promarker D and Promarker Eso blood tests through Healius, while a A$2 million tax incentive receipt has lifted pro forma cash to A$3.8 million. Promarker Endo also cleared an independent Oxford validation hurdle, but its commercial launch remains conditional.
Ada Torres
Ada Torres
30 Oct 2026
Alligator Energy has extended uranium mineralisation south of its Blackbush resource at Samphire while field recovery results feed into the project feasibility study. A $17.1 million capital raising and other receipts lifted quarter-end cash to $25.4 million.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Strategic Elements has moved its EdgeiQ platform closer to commercial mining pilots while Energy Ink progresses towards a system-level demonstration. The ASX-listed venture developer ended September with $3.918 million in cash and an estimated 4.32 quarters of funding at the quarter’s spending rate.
Sophie Babbage
Sophie Babbage
30 Oct 2026

Browse the archive

Full archive